

# Appendix 3Y

## Change of Director's Interest Notice

*Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.*

Introduced 30/09/01 Amended 01/01/11

<b>Name of entity</b> Clarity Pharmaceuticals Ltd
<b>ABN</b> 36 143 005 341

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

<b>Name of Director</b>	Colin David Biggin
<b>Date of last notice</b>	21 February 2023

### Part 1 - Change of director's relevant interests in securities

*In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Direct or indirect interest</b>	Direct
<b>Nature of indirect interest (including registered holder)</b> <small>Note: Provide details of the circumstances giving rise to the relevant interest.</small>	n/a
<b>Date of change</b>	1 July 2023
<b>No. of securities held prior to change</b>	<ul style="list-style-type: none"> <li>• 1,106,308 fully paid ordinary shares</li> <li>• 1,000,000 options exercisable at \$0.22 each on or before 1 July 2023</li> <li>• 600,000 options exercisable at \$0.605 each on or before 1 July 2024</li> <li>• 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025.</li> <li>• 837,855 options exercisable at \$0.508 each on or before 24 November 2027</li> </ul>
<b>Class</b>	Shares

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

<b>Number acquired</b>	694,996 shares
<b>Number disposed</b>	1,000,000 options exercisable at \$0.22 each on or before 1 July 2023.
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and estimated valuation	\$152,899.12
<b>No. of securities held after change</b>	<ul style="list-style-type: none"> <li>• 1,801,304 fully paid ordinary shares</li> <li>• 600,000 options exercisable at \$0.605 each on or before 1 July 2024</li> <li>• 1,000,000 options exercisable at \$0.605 each on or before 1 October 2024</li> <li>• 1,200,000 options exercisable at \$0.825 each on or before 18 December 2024</li> <li>• 1,000,000 options exercisable at \$0.938 each on or before 1 July 2025.</li> <li>• 837,855 options exercisable at \$0.508 each on or before 24 November 2027</li> </ul>
<b>Nature of change</b> Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back	Exercise of 1,000,000 options via cashless exercise applying a share price of \$0.7213 being the 5 day VWAP up to and including 30 June 2023.

**Part 2 – Change of director's interests in contracts**

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

<b>Detail of contract</b>	n/a
<b>Nature of interest</b>	n/a
<b>Name of registered holder (if issued securities)</b>	n/a
<b>Date of change</b>	n/a
<b>No. and class of securities to which interest related prior to change</b> Note: Details are only required for a contract in relation to which the interest has changed	n/a
<b>Interest acquired</b>	n/a

+ See chapter 19 for defined terms.

**Appendix 3Y**  
**Change of Director's Interest Notice**

---

<b>Interest disposed</b>	n/a
<b>Value/Consideration</b> Note: If consideration is non-cash, provide details and an estimated valuation	n/a
<b>Interest after change</b>	n/a

**Part 3 – <sup>+</sup>Closed period**

<b>Were the interests in the securities or contracts detailed above traded during a <sup>+</sup>closed period where prior written clearance was required?</b>	No
<b>If so, was prior written clearance provided to allow the trade to proceed during this period?</b>	n/a
<b>If prior written clearance was provided, on what date was this provided?</b>	n/a

---

<sup>+</sup> See chapter 19 for defined terms.